Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)
Conditions: Recurrent Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer Stage IV Interventions: Drug: Nivolumab + Paclitaxel; Drug: Cetuximab + Paclitaxel Sponsors: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello; Bristol-Myers Squibb; Apices Soluciones S.L. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Head and Neck Cancer | Research | Study